Risk factor
Very high price volatility
Profitability factor
Slightly undervalued vs peers
About
Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on
Target Price
The average target price of PEL.NS is 1254 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
